Welcome to our dedicated page for PolyPid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PolyPid Ltd. filings document foreign private issuer disclosures for a biopharmaceutical company developing PLEX-based controlled-release therapeutics. Form 6-K reports furnish corporate updates, financial results, FDA and NDA-related disclosures for D-PLEX100, SHIELD II clinical and pharmacokinetic information, GMP inspection updates, and business-operation summaries.
The company’s regulatory record also covers capital-structure and governance matters, including ordinary-share sales agreement disclosures, legal opinions tied to share issuance, Form F-3 and Form S-8 registration statement references, shareholder meeting results, board composition, director compensation approvals, and risk and operating disclosures incorporated into its SEC registration framework.
Stein Robert Benjamin reported acquisition or exercise transactions in this Form 4 filing.
PolyPid Ltd. director Robert Benjamin Stein received a grant of 9,132 stock options to purchase Ordinary Shares at $4.46 per share. The options vest on a quarterly basis beginning July 15, 2026 until April 15, 2030 and expire on July 15, 2036. Following this grant, he holds 9,132 options directly.
PolyPid Ltd. director Dror-Darwish Nir received a grant of stock options covering 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share, vest quarterly beginning July 15, 2026 until April 15, 2030, and expire on July 15, 2036. Following this award, he holds options for 9,132 shares, reported as direct ownership. The transaction is categorized as a grant or award acquisition rather than an open-market trade.
PolyPid Ltd. director Joseph BenAmram reported a compensation grant of stock options to acquire 9,132 Ordinary Shares. The options have an exercise price of $4.46 per share and expire on July 15, 2036. They vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and this award brings his reported stock option holdings to 9,132 options.
PolyPid Ltd. reported that director Itzhak Krinsky received a grant of stock options for 9,132 Ordinary Shares at an exercise price of $4.4600 per share. The options vest on a quarterly basis from July 15, 2026 until April 15, 2030 and expire on July 15, 2036.
PolyPid Ltd. director Story Brooke received a grant of 9,132 stock options to acquire Ordinary Shares at an exercise price of 4.4600 per share. All 9,132 options are held directly, vest on a quarterly basis beginning July 15, 2026 until April 15, 2030, and expire July 15, 2036.
PolyPid Ltd. granted 149,000 stock options to Chief Executive Officer Akselbrad Dikla Czaczkes. The options relate to Ordinary Shares at an exercise price of $4.46 per share, vest quarterly from May 11, 2026 through May 11, 2030, and expire on July 15, 2036.
PolyPid Ltd. held an Annual and Extraordinary General Meeting of Shareholders on July 15, 2026, where a quorum was present and shareholders approved all four proposals. These included re-electing Kost Forer Gabbay & Kasierer as independent auditors, re-electing eight directors and approving their compensation, amending non-executive directors’ annual option grants, and approving an option grant for Chief Executive Officer Dikla Czaczkes Akselbrad.
Separately, on May 11, 2026, the board approved increasing the ordinary shares reserved for issuance under PolyPid’s Amended and Restated 2012 Share Option Plan by 1,500,000, from 3,512,403 to 5,012,403 shares. The plan sets eligibility for employees, officers, directors, consultants and other service providers, a standard four-year vesting schedule, repurchase rights upon termination for cause, and detailed tax and transfer rules, including Israeli and U.S. tax sub-plans.
PolyPid Ltd. is calling an annual and extraordinary general meeting of shareholders on July 15, 2026 in Petach Tikva, Israel. Shareholders of record at the close of business on June 15, 2026 may vote in person or by proxy.
On the agenda are proposals to re-elect Kost Forer Gabbay & Kasierer (EY) as independent auditors, re-elect eight directors and approve their cash and option compensation, amend the terms of annual option grants for non-executive directors, and grant options over up to 149,000 ordinary shares to CEO Dikla Czaczkes Akselbrad. Shareholders will also discuss, but not vote on, the 2025 audited financial statements and Form 20-F.
PolyPid Ltd. has completed its New Drug Application submission to the U.S. FDA for D-PLEX100, its lead drug candidate to prevent surgical site infections in patients undergoing colorectal surgery. The FDA review is following a PDUFA timeline with a target action date in the first quarter of 2027.
The NDA is backed by the Phase 3 SHIELD II trial, where D-PLEX100 met its primary and all key secondary endpoints and showed a 60% relative risk reduction in surgical site infections versus standard of care (p=0.0013). D-PLEX100 delivers local, controlled release of doxycycline at the wound site for about 30 days and has FDA Breakthrough Therapy, Fast Track and Qualified Infectious Disease Product designations, supporting eligibility for Priority Review.
PolyPid Ltd. reported a net loss of $7,728 thousand for the first quarter of 2026, slightly improved from $8,268 thousand a year earlier. Operating expenses totaled $7,760 thousand, driven mainly by research and development of D-PLEX₁₀₀, which is now under an initiated NDA submission to the FDA.
Cash and cash equivalents were $8,888 thousand as of March 31, 2026, with total current assets of $12,560 thousand. Shareholders’ equity stood at $8,780 thousand, supported by additional paid-in capital of $318,008 thousand. Management highlighted late-stage U.S. commercial partnership discussions and reiterated expectations that existing cash resources can fund operations into the second half of 2026.